Who Paid My Doc
Nathan Becker
Endocrinology, Diabetes & Metabolism San Francisco, CA Medical Doctor
NPI 1972696250 CMS profile 43930
350 Parnassus Ave, Suite 707, San Francisco, CA 94117
General payments
$3,822
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Nathan Becker of San Francisco, CA is reported in the CMS Open Payments database as having received $3,822 across 216 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 63rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $531 | 28 | |
| 2024 | General | $668 | 28 | |
| 2023 | General | $542 | 24 | |
| 2022 | General | $764 | 46 | |
| 2021 | General | $553 | 29 | |
| 2020 | General | $93 | 5 | |
| 2019 | General | $672 | 56 |
Beside peers
- Nathan Becker
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Nathan Becker were reported at $531. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Nathan Becker | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $672 | $494 | $123–$2,253 | $163 |
| 2020 | $93 | $335 | $85–$1,841 | $114 |
| 2021 | $553 | $398 | $88–$1,981 | $132 |
| 2022 | $764 | $364 | $88–$1,568 | $149 |
| 2023 | $542 | $420 | $113–$1,614 | $160 |
| 2024 | $668 | $440 | $121–$1,646 | $164 |
| 2025 | $531 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
3,783
Drug cost
$672,717
Branded share of claims
61.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rybelsus Semaglutide | Brand | 118 | $155,791 | |
| Synthroid Levothyroxine Sodium | Brand | 931 | $91,065 | |
| Forteo Teriparatide | Brand | 18 | $75,758 | |
| Tirosint Levothyroxine Sodium | Brand | 251 | $57,476 | |
| Jardiance Empagliflozin | Brand | 52 | $57,123 | |
| Liothyronine Sodium | Generic | 773 | $45,417 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 34 | $39,491 | |
| Ozempic Semaglutide | Brand | 26 | $33,076 | |
| Januvia Sitagliptin Phosphate | Brand | 30 | $22,914 | |
| Tirosint-Sol Levothyroxine Sodium | Brand | 88 | $22,347 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 10 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| JARDIANCE |
|
$142 | 52 | — |
| Tirosint |
|
$108 | 339 | — |
| Licart |
|
$108 | — | — |
| MOUNJARO |
|
$85 | — | — |
| SYNTHROID |
|
$62 | 931 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 10 in the dashboard with a free accountRecords
216 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in California
Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CA
Joselito Cabaccan
Endocrinology, Diabetes & Metabolism · San Jose, CA
Daniel Nadeau
Endocrinology, Diabetes & Metabolism · Newport Beach, CA
Yehuda Handelsman
Endocrinology, Diabetes & Metabolism · Tarzana, CA
Helen Baron
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CA
Ken Fujioka
Endocrinology, Diabetes & Metabolism · San Diego, CA
Related records
Endocrinology, Diabetes & Metabolism in California
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.